Do you want to read an article? Please log in or register.
Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Psoriasis and Comorbid Type 2 Diabetes: A Population-based Target Trial Emulation
Psoriasis
Related content
COMMENTED
Rheumatoid Arthritis
Comparative risk of rheumatoid arthritis between glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in type 2 diabetes
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
J Autoimmun
Yen FS, Wang SI, Hwu CM, Haung CW, Chang R, Hsu CC, Wei JC
doi: 10.1016/j.jaut.2025.103493
Gout
Comparative Cardiovascular Safety of NSAID versus Colchicine Use When Initiating Urate-Lowering Therapy Among Patients with Gout: Target Trial Emulations
Arthritis Rheumatol
Yokose C, McCormick N, Lu N, Jiang B, Tan K, Chigurupati S, Rai S, Challener G, Aviña-Zubieta JA, Cipolletta E, Abhishek A, Gaffo A, Januzzi JL, Zhang Y, Choi HK
doi: 10.1002/art.43259
Psoriasis
Efficacy and safety of apremilast in pediatric patients with moderate to severe plaque psoriasis: 52-week results from the SPROUT randomized controlled trial
Br J Dermatol
Paller AS, Fiorillo L, Becker E, Armesto S, Kontzias A, Oberoi RK, Zhang W, Amouzadeh H, Zhang Z, Arkin L
doi: 10.1093/bjd/ljaf305
Systemic Lupus Erythematosus
Effects of sodium-glucose transporter 2 inhibitors in patients with lupus nephritis: a before-and-after retrospective cohort study
Rheumatology (Oxford)
Ramírez-Mulhern I, Navarro-Sánchez V, Rivero-Otamendi E, Sánchez-Mejía DE, Zavala-Miranda MF, Mejia-Vilet JM
doi: 10.1093/rheumatology/keaf548
Acne
Bimekizumab demonstrated a favorable safety profile and high levels of efficacy with up to 2 years of treatment in patients with moderate to severe hidradenitis suppurativa: Pooled results from two phase 3 randomized, controlled trials and their open-label extension
J Am Acad Dermatol
Sayed CJ, Kirby B, Garg A, Naik HB, Kimball AB, Zouboulis CC, Jemec GBE, Kokolakis G, Ingram JR, Morita A, Deherder D, Crater C, Rolleri RL, Vaux T, Lambert J, Lukowski B, Bechara FG
doi: 10.1016/j.jaad.2025.11.031
Vitiligo
Efficacy and Safety of the Oral Janus Kinase 1 Inhibitor Povorcitinib in Patients With Extensive Vitiligo in a Phase 2, Randomized, Double-Blinded, Dose-Ranging, Placebo-Controlled Study
J Am Acad Dermatol
Pandya AG, Ezzedine K, Passeron T, van Geel N, Brown K, Santos LL, Erskine L, Wagya K, Blauvelt A
doi: 10.1016/j.jaad.2025.06.027
Psoriasis
Bimekizumab efficacy and safety in Chinese patients with psoriasis in the BE SHINING Phase 3 study
J Eur Acad Dermatol Venereol
Cai L, Man XY, Wang J, Wei A, Chen Y, Deherder D, Gao J, Hoepken B, Sun W, Lei T, Zhang J, BE SHINING Study Group
doi: 10.1111/jdv.70350
Psoriasis
Long-term safety and efficacy of secukinumab in paediatric severe plaque psoriasis: 236-week, Phase 3 trial results
J Eur Acad Dermatol Venereol
Kaszuba A, Papanastasiou P, Krasowska D, De Lucas Laguna R, Ziv M, Ravichandran S, Bansal A, Dahale SS, Martin R, Paguet B, Magnolo N, Kingo K
doi: 10.1111/jdv.70155
Rheumatoid Arthritis
Efficacy and safety of izokibep in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study
Ann Rheum Dis
Taylor PC, Mease PJ, de Vlam K, Mpofu S, Wetzel D, Stevens AM, Wiens B, Koskinen LO, Ohlman S, Feldwisch J, Frejd FY, Brun NC, Brandt-Juergens J, Drescher E, Dokoupilova E, Rowińska-Osuch A, Abdel-Kader Martin N, Behrens F
doi: 10.1016/j.ard.2025.02.019